FDA Approves Semaglutide for PAD: 13% Improvement in Walking Distance in STRIDE Trial

Executive Brief

News Report

The News: FDA approves semaglutide for PAD, showing significant functional improvement.
Clinical Win: The approval offers a new treatment option for patients with PAD and type 2 diabetes.
Target Specialty: cardiology

Key Data at a Glance

Improvement in walking distance: 13%
Participants enrolled: 792
Average age of participants: 68 years

The FDA approved semaglutide (Ozempic) for the treatment of peripheral artery disease (PAD) in patients with type 2 diabetes, demonstrating a 13% improvement in walking distance compared to placebo in the STRIDE trial (estimated treatment ratio, 1.13; 95% CI, 1.06-1.21) [1]. This approval, announced in March 2025, highlights the potential of semaglutide to improve functional outcomes in a population with significant cardiovascular risk.

Clinical Context

Peripheral artery disease (PAD) is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs, leading to symptoms such as leg pain during physical activity. Patients with PAD are at increased risk for cardiovascular events, including heart attack and stroke. Current treatment options primarily focus on lifestyle modifications and symptom management, but there remains a significant unmet need for effective pharmacological interventions that can improve walking capacity and overall quality of life. Semaglutide, a GLP-1 receptor agonist, has previously shown efficacy in managing type 2 diabetes and reducing cardiovascular risk. The STRIDE trial aimed to evaluate the impact of semaglutide on functional outcomes in patients with symptomatic PAD and type 2 diabetes, addressing this critical gap in treatment options.

Key Findings

The trial enrolled 792 participants with symptomatic PAD and type 2 diabetes, aged 68 years on average, with 25% women and 68% White [1].
Event rates: 40 meters average improvement in walking distance for semaglutide vs placebo [1].
The primary endpoint was the change in walking distance measured by a constant-load treadmill test at baseline, 26, and 52 weeks [1].

Safety & Tolerability

The STRIDE trial showed semaglutide (Ozempic) reduced walking distance improvement by 13% versus placebo (estimated treatment ratio, 1.13; 95% CI, 1.06-1.21) [1].

What This Means for Clinical Practice

Semaglutide is now indicated for patients with type 2 diabetes and symptomatic PAD, providing a new pharmacological option to improve walking capacity and quality of life. The 13% improvement in walking distance is clinically relevant, especially for patients who struggle with mobility due to PAD. Clinicians should consider integrating semaglutide into treatment plans for eligible patients, particularly those who have not responded adequately to lifestyle modifications or other therapies. The implications for patient outcomes are significant, as improved walking capacity can enhance daily functioning and reduce the risk of cardiovascular events. However, ongoing monitoring for adverse effects and patient response to therapy will be essential as this new indication is implemented in clinical practice.

Clinical Perspective

Workflow: Clinicians can now prescribe semaglutide for patients with PAD and type 2 diabetes, enhancing treatment options.

Economics: The introduction of semaglutide may reduce long-term healthcare costs associated with PAD complications.

Patient Outcomes: Improved walking capacity can lead to better quality of life and reduced cardiovascular risks for patients.

Dr. Arjun Sharma, Cardiology

FDA Approves Semaglutide for PAD: 13% Improvement in Walking Distance in STRIDE Trial

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

Baxdrostat Targets Aldosterone Pathway: New Algorithm for Resistant Hypertension Management

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

FDA Approves Semaglutide for HFpEF: 52% Improvement in Heart Failure Symptoms

Verified HCP Portal